Skip to main content

#162063

Anti-Anterior gradient 3 [AGR3.1]

Cat. #162063

Anti-Anterior gradient 3 [AGR3.1]

Cat. #: 162063

Sub-type: Primary antibody

Availability: 3-4 weeks

Target: Anterior gradient 3

Class: Monoclonal

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Moravian Biotechnology

Tool Details
Target Details
Handling

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Anterior gradient 3 [AGR3.1]
  • Clone: AGR3.1
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: Calculated: 19,6 kDa; SDS-PAGE mobility (reduced): 19-20 kDa.
  • Reactivity: Human
  • Host: Mouse
  • Description: Antibody created to detect the endogenous AGR3 protein in both cytosolic and membrane fractions of breast cancer cells (with higher affinity than the AGR3.2 antibody). Binding specificity: Human AGR3 protein. Epitope HETTDKNLS (determined using pepscan).
  • Immunogen: Purified human AGR3 protein
  • Isotype: IgG1 kappa
  • Production details: B cell donor: Splenocytes from mouse immunised with purified AGR3 protein, fusion partner: SP2

Target Details

  • Target: Anterior gradient 3
  • Molecular weight: Calculated: 19,6 kDa; SDS-PAGE mobility (reduced): 19-20 kDa.
  • Target background: AGR3 (Anterior Gradient 3) is a human homologue of the XAG-2 protein expressed in Xenopus laevis, which was identified in a study analyzing mRNA expression in ER-positive breast cancer-derived cell lines. The coding sequence of the AGR3 protein is located on the chromosome at position 7p21. AGR3 expression in ovarian cancer is independent of oestrogen-receptor expression, which is distinct from the oestrogen-receptor dependent expression of AGR3 in breast cancers. Isogenic cancer cell models were created that over-express AGR3 and these demonstrated that AGR3 mediates cisplatin-resistance in mouse xenografts. These data indicate that AGR3 is over-expressed by a hormone (oestrogen-receptor ?)-independent mechanism and identify a novel protein-folding associated pathway that could mediate resistance to DNA-damaging agents in human cancers.
  • Epitope sequence: HETTDKNLS sequence of Anterior gradient 3

Handling

  • Format: Liquid
  • Shipping conditions: Dry ice

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.